First Tracks reported quarterly Earnings Per Share of $-1.45, falling short of the $-0.53 consensus by $0.92, widening its loss gap and signalling higher downside risk for investors. The miss highlights the need for near‑term clinical data and cash‑flow discipline as the company continues to fund multiple Phase 1b trials.
Key Highlights
- FDA Fast Track Designation for ANB033 in celiac disease strengthens pipeline outlook
- Cash runway extends into Q2 2028, supporting development of multiple indications
- First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX) sits at a $1.6 billion Market Capitalisation with 35,390,679 shares outstanding and $168.0 million in cash and equivalents.
First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX) sits at a $1.6 billion market capitalisation with 35,390,679 shares outstanding and $168.0 million in cash and equivalents. The loss widened to $33.4 million for the quarter and $83.9 million for the first half of the year, while Research and Development expenses fell to $25.6 million and $59.6 million respectively. These results arrived as the company secured FDA Fast Track status for its CD122 antagonist ANB033, positioning it for accelerated development in celiac disease.
EPS Miss Deepens Loss Gap
The miss aligns with a broader trend of rising expenses, as R&D spend dropped from $39.3 million to $25.6 million, primarily due to lower rosnilimab costs but higher ANB033 trial outlays. General and administrative expenses rose to $9.3 million from $6.6 million, driven by legal fees associated with the recent separation from AnaptysBio. While the net loss narrowed versus the prior year, the widened per‑share loss highlights the need for upcoming clinical readouts to justify the cash burn.
Investors must assess whether the forthcoming data can offset the deeper-than‑expected earnings dip.
Clinical Milestones and Fast Track Status
The Phase 1b trial in celiac disease now comprises two cohorts: Cohort 1 (30 patients) evaluating gluten‑challenge protection, with top‑line data reaffirmed for the fourth quarter of 2026; and Cohort 2 (40 patients) assessing mucosal healing, with results expected in the first quarter of 2027. Simultaneously, a 50‑patient Phase 1b study in eosinophilic esophagitis progresses toward a Q3 2027 data readout. The company also plans to launch Phase 2 trials in two additional indications during the first half of 2027.
These milestones aim to broaden ANB033’s therapeutic footprint, but the timeline places important data releases several quarters away, extending the period of cash reliance.
Cash Position and Burn Rate
First Tracks reported $168.0 million of cash and equivalents as of June 30 2026, projecting a runway that stretches into the second quarter of 2028. The cash reserve, while sizable, must support the expanded Phase 1b programs for ANB033 and the anticipated Phase 2 launches. With R&D outlays at $59.6 million for the six‑month period and administrative costs at $28.1 million, the Burn Rate remains elevated.
Short interest fell to 11% of shares outstanding, a 17% reduction from the prior settlement, indicating a modest easing of bearish pressure. Sector peers exhibited mixed moves, with ZYME down 2.7%, ABSI up 1.9%, and XNCR up 0.2% on the day, suggesting that competitive dynamics are not driving First Tracks’ share performance. Maintaining sufficient Liquidity will be critical as the company funds multiple trials across four indications.
Outlook and Upcoming Catalysts
Technical indicators show the stock trading above its 20‑day Moving Average of $42.32 and its 50‑day average of $29.22, reinforcing a bullish near‑term structure. The 14‑day RSI of 66.8 signals elevated momentum, while the MACD of 5.06 sits just below its signal line of 5.43, hinting at a potential softening. Investors will watch for the Q4 2026 top‑line results from Cohort 1 of the ANB033 celiac disease trial, a catalyst that could validate the Fast Track designation and influence valuation.
A subsequent data release in Q1 2027 from Cohort 2, followed by eosinophilic esophagitis results in Q3 2027, will further shape the company’s outlook. The ability to translate these clinical milestones into commercial potential will determine whether the current cash runway can sustain long‑term growth.
Peers Moving on This News
- Zymeworks Inc (NASDAQ: ZYME) down 2.7%
- Absci Corp (NASDAQ: ABSI) up 1.9%
- Xencor Inc (NASDAQ: XNCR) up 0.2%






Please wait processing your request...